Tarun Nagrani, MD
Cardiovascular Disease · Portsmouth, OHNPI 1427203652
Payments from drug & device makers
Across 42 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$465
- Cardiovascular Systems Inc.$99
- Astellas Pharma US Inc$82
- Celonova Biosciences, Inc.$67
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$22
What the payments were for
- Food & beverage$65289%
- Education$8211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 33 | $465 |
| Cardiovascular Systems Inc. | 4 | $99 |
| Astellas Pharma US Inc | 1 | $82 |
| Celonova Biosciences, Inc. | 1 | $67 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $22 |
How this compares
$734 in reported general payments places this provider in the 35th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 351 | $413,557 |
| XareltoRivaroxaban | 351 | $404,336 |
| EntrestoSacubitril/Valsartan | 176 | $223,345 |
| Repatha SureclickEvolocumab | 52 | $72,691 |
| Prasugrel Hcl | 336 | $46,288 |
| Praluent PenAlirocumab | 38 | $30,211 |
| BrilintaTicagrelor | 28 | $26,051 |
| Ranolazine ErRanolazine | 285 | $21,468 |
| MultaqDronedarone Hcl | 15 | $18,240 |
| FarxigaDapagliflozin Propanediol | 13 | $16,225 |
| Metoprolol Succinate | 937 | $13,929 |
| Nifedipine ErNifedipine | 322 | $8,165 |
| Potassium Chloride | 476 | $7,894 |
| Atorvastatin Calcium | 943 | $7,531 |
| Mexiletine Hcl | 34 | $5,700 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Portsmouth
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
- Guilherme AttizzaniCleveland$2.8M
- Wai Hong TangCleveland$2.2M
- Bhola RamaMarion$2.1M
- Mazen HannaCleveland$1.6M
- Akber MohammedSpringfield$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.